跳至主要内容
临床试验/NCT00851916
NCT00851916Unknown2 期

VIRTUAL HDR CYBERKNIFE RADIOSURGERY FOR LOCALLY RECURRENT PROSTATIC CARCINOMA: A PHASE II STUDY

CyberKnife Centers of San Diego1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2009年2月1日最近更新:
适应症
干预措施

试验速览

阶段
2 期
发起方
入组人数
20
试验地点
1
主要终点
Establish pattern of PSA decline

研究概览

简要总结

The purpose of this study is to scientifically evaluate the effects (good and bad) of a new type of radiation treatment in patients with locally recurrent prostate cancer after prior radiotherapy. The treatment is known as prostate radiosurgery, and is distinguished from traditional radiotherapy by the application of smaller, more precisely controlled margins around the area targeted for full dose radiation, and far fewer treatments, using a much larger dose per treatment.

This research is being done to see what advantages, if any, prostate radiosurgery may have over other salvage treatment methods, including brachytherapy, cryosurgery, high intensity focused ultrasound (HIFU), hormonal therapy and radical prostatectomy.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者
否

入选标准

  • •Histologically confirmed recurrent adenocarcinoma of the prostate, clinical stage T1 - T3 (AJCC 6th Edition, see Appendix II), NX/N0, M0, following prior prostate radiotherapy.
  • •Karnofsky performance status >
  • •Greater than 5 year life expectancy
  • •Greater than 2 years since the original course of radiotherapy.
  • •Absence of distant metastases by radiologic or pathologic assessment.
  • •Absence of lymph node involvement by radiologic or pathologic assessment.
  • •Patients must sign a study-specific informed consent form prior to study entry.

排除标准

  • •Stage T4 disease (AJCC 6th Edition, see Appendix II).
  • •Less than 2 years since the original course of radiotherapy.
  • •Lymph node involvement (N1).
  • •Evidence of distant metastases (M1).
  • •Radical surgery for carcinoma of the prostate
  • •Previous or concurrent cancers other than basal, in situ, or squamous cell skin cancers unless disease-free for ≥ 5 years.
  • •Major medical or psychiatric illness, which in the investigator's opinion, would prevent completion of treatment and would interfere with follow-up.
  • •History of inflammatory bowel disease
  • •Late GI or GU Morbidity > Grade 1 from the prior course of radiotherapy

研究组 & 干预措施

CyberKnife Radiosurgery

Other

Single arm study using CyberKnife radiosurgery to treat recurrent prostate cancer patients that have already received external beam radiotherapy.

干预措施: CyberKnife Radiosurgery (Radiation)

结局指标

主要结局

Establish pattern of PSA decline

时间窗: Post CyberKnife Radiosurgery - 5 year f/up

次要结局

  • Quality of Life realitive to other commonly used radiation treatment methods for recurrent prostate cancer(Post CyberKnife Radiosurgery/5 yr. f/up)

研究者

发起方
CyberKnife Centers of San Diego
申办方类型
Other
责任方
Principal Investigator
主要研究者

Carlyn Tripp

Donald Fuller, M.D.

CyberKnife Centers of San Diego

研究点 (1)

Loading locations...

相似试验